Literature DB >> 1867224

Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia.

J M Flack1, J R Sowers.   

Abstract

Epidemiologic studies have shown that insulin is a risk factor for coronary heart disease (CHD). Clinical studies have also demonstrated positive correlations between insulin and blood pressure, triglycerides, total cholesterol, fibrinogen, and plasminogen activator inhibitor. Moreover, there is an inverse correlation between insulin and high-density lipoprotein (HDL). These studies have provided evidence in support of the biologic plausibility of epidemiologic observations, but they have not clearly established insulin's role in the pathogenesis of human cardiovascular diseases (CVD) such as hypertension. In fact, there is considerable evidence that insulin resistance (abnormal nonoxidative glucose disposal), not hyperinsulinemia, is the primary insulin-related abnormality in human hypertension, and that hyperinsulinemia occurs as a response to insulin resistance. Skeletal muscle appears to be the primary site of insulin resistance in essential hypertension, although other organs, such as the kidneys and liver--key sites for cell and water homeostasis and lipoprotein regulation, respectively--may respond normally to insulin. Adipocytes also appear to be a site of insulin resistance. Thus, the putative interrelationship between hyperinsulinemia and insulin resistance, on the one hand, and with blood pressure and lipoproteins, on the other, is a complex one and may involve organ-specific insulin resistance. Altered cation transport is one of several mechanisms by which insulin resistance might raise blood pressure. The Na+, K(+)-ATPase and Ca(2+)-ATPase pumps are insulin sensitive. Thus, when insulin resistance is present, the activity of these pumps in the smooth muscle of the arterial wall might be reduced. This would lead to an intracellular accumulation of sodium and calcium, thereby sensitizing the vascular wall to pressor substances. Moreover, secondary hyperinsulinemia will occur, and insulin has been shown to stimulate sympathetic nervous system activity and to increase renal tubular absorption of sodium. Insulin is also a growth factor and therefore might have a trophic effect on the vessel wall, one that could initiate and/or sustain hypertension as well as atherosclerosis. Abnormal lipoprotein metabolism is yet another possible explanation for the accelerated atherosclerosis that has been observed in persons with abnormal carbohydrate tolerance and insulin resistance. Hyperinsulinemia and insulin resistance both play a role in the expression of elevated very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) levels as well as in the depression of HDL levels. Coronary risk reduction has been disappointing when blood pressure has been lowered with treatment regimens based on thiazide diuretics and/or beta blockers. Thiazides and some beta blockers may further impair tissue insulin sensitivity and often cause blood lipoprotein abnormalities.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867224     DOI: 10.1016/0002-9343(91)90058-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Diagnosing diabetes. A practitioner's plea: keep it simple.

Authors:  A Fournier
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

Review 2.  Obesity, hypertension, and vascular disease.

Authors:  K M Sowers; J R Sowers
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

3.  Insulin resistance, hyperinsulinemia, and cardiovascular disease. The need for novel dietary prevention strategies.

Authors:  H Rupp
Journal:  Basic Res Cardiol       Date:  1992 Mar-Apr       Impact factor: 17.165

4.  Role of aldehydes in fructose induced hypertension.

Authors:  S Vasdev; C A Ford; L Longerich; V Gadag; S Wadhawan
Journal:  Mol Cell Biochem       Date:  1998-04       Impact factor: 3.396

Review 5.  Treatment of hypertension in the presence of coexisting medical conditions.

Authors:  J Kvasnicka; J M Flack; R H Grimm
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

6.  Sympathoadrenergic overactivity and lipid metabolism.

Authors:  A Grynberg; D Ziegler; H Rupp
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

Review 7.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 8.  Beneficial effect of low ethanol intake on the cardiovascular system: possible biochemical mechanisms.

Authors:  Sudesh Vasdev; Vicki Gill; Pawan K Singal
Journal:  Vasc Health Risk Manag       Date:  2006

Review 9.  Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.

Authors:  Sanjib Kumar Sharma; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Vasc Health Risk Manag       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.